Labrador develops a needle-free diagnostic device for at-home screening of diabetes and chronic kidney disease, enabling users to conduct noninvasive tests anytime and anywhere. This technology addresses the issue of late diagnosis, as a significant percentage of individuals with these conditions remain unaware of their health status.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
A significant percentage of individuals with diabetes and chronic kidney disease (CKD) are unaware of their condition due to late diagnosis, hindering timely treatment and management. Traditional diagnostic methods often require clinic visits, which can be inconvenient and contribute to delayed detection.
Solution
Labrador is developing a needle-free diagnostic device designed for convenient at-home screening of diabetes and CKD. This non-invasive technology allows users to conduct tests anytime and anywhere, facilitating early detection and proactive management of these chronic diseases. By enabling frequent and accessible testing, Labrador aims to address the issue of late diagnosis and empower individuals to take control of their health.
Target Audience
The primary target audience includes individuals at risk of or with early-stage diabetes and chronic kidney disease, as well as healthcare providers seeking accessible screening tools.
Features
- Needle-free diagnostic technology for non-invasive testing.
- At-home testing capability for convenient and accessible screening.
- Focus on early detection of diabetes and chronic kidney disease.